51,181 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Purchased by Virtu Financial LLC

Virtu Financial LLC acquired a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 51,181 shares of the company’s stock, valued at approximately $222,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Cardiff Oncology by 1.9% in the third quarter. Geode Capital Management LLC now owns 928,232 shares of the company’s stock valued at $2,479,000 after purchasing an additional 17,557 shares during the period. State Street Corp grew its stake in Cardiff Oncology by 3.4% in the 3rd quarter. State Street Corp now owns 832,652 shares of the company’s stock valued at $2,223,000 after buying an additional 27,628 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Cardiff Oncology by 68.7% during the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock valued at $1,253,000 after acquiring an additional 117,514 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Cardiff Oncology by 11.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock worth $324,000 after acquiring an additional 12,503 shares in the last quarter. Finally, XTX Topco Ltd lifted its position in shares of Cardiff Oncology by 44.3% during the third quarter. XTX Topco Ltd now owns 120,384 shares of the company’s stock worth $321,000 after acquiring an additional 36,947 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright lifted their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 28th.

Cardiff Oncology Price Performance

Shares of NASDAQ:CRDF opened at $3.29 on Friday. The firm has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $3.44. The company has a market cap of $218.86 million, a price-to-earnings ratio of -3.50 and a beta of 1.73. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $6.38.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.